Project Grant K99CA286721
Award Date
6/1/24
Completion Date
5/31/26
Dollars Obligated
$519K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
This $1,944,610.00 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program will fund research conducted by the Sloan-Kettering Institute for Cancer Research to understand tumorigenesis and identify therapeutic targets in CDK12-mutant prostate cancer. The award, with a performance period from April 1, 2025 to March 31, 2028, will support the institute's innovative scientific investigations into the underlying...
This federal Project Grant award for $704,000.00, awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research by the Sloan-Kettering Institute for Cancer Research in New York, NY. The research aims to investigate the role of the NF-I/A transcription factor in regulating fatty acid metabolism in kidney cancer. This multi-year project will run from September 1, 2024 to August 31, 2028. As the prime grantee, the Sloan-Kettering...
This federal Project Grant award of $2,808,108.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by the Sloan-Kettering Institute for Cancer Research to investigate the role of clonal hematopoiesis in therapeutic resistance and metastatic relapse in breast cancer. The award period extends from March 1, 2024 to February 29, 2028. Through this funding, the Sloan-Kettering Institute will explore the...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $158,020.00 in funding to the Sloan-Kettering Institute for Cancer Research to investigate the role of mutagenic DNA repair during the persistence of cancer cells. The key products and services to be delivered under this award include: Investigating persistence in response to PARP inhibitor treatment of BRCA1/2 mutant cancer cells to understand the mechanisms of mutagenic DNA repair,...
The federal Project Grant award of $924,001.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports research by the Sloan-Kettering Institute for Cancer Research to investigate the cellular and molecular origins of non-small cell lung cancer (NSCLC) brain metastasis. The research aims to enhance understanding of the mechanisms driving NSCLC brain metastasis, with the goal of developing innovative therapeutic...
This federal Project Grant award of $432,168.00 from the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) program supports research at the Sloan-Kettering Institute for Cancer Research in New York, NY. The project aims to develop computational models that can quantitatively predict how clinical kinase mutations impact drug resistance, activity, and sensitivity in cancer treatment. Specifically, the research will utilize binding free-energy calculations and...
This federal Project Grant award of $708,000.00 provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research conducted by the Sloan-Kettering Institute for Cancer Research, a non-profit organization located in New York, NY. The research project is focused on investigating the "Prevalence and Biologic Impact of FGFR3 Genomic Alterations in Bladder Cancer". The 2-year award period runs from September 15, 2023 to...
Sloan-Kettering Institute For Cancer Research was awarded a $845,789 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) for the period of July 1, 2023 to June 30, 2026. The grant will support research to discover biomarkers and address outcome disparities for prostate cancer through exploiting real-world clinical genomic data. As the prime recipient, Sloan-Kettering Institute For Cancer Research will leverage its expertise...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), supports research to investigate mechanisms underlying T-cell dysfunction within the tumor microenvironment. The $103,948 award will be used by the Sloan-Kettering Institute for Cancer Research to conduct two primary research aims: 1) Determine how local amino acid availability impacts the exhausted T-cell proteome and T-cell function, and 2) Examine...
The National Cancer Institute (NCI) awarded a $116,720 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to The Research Foundation for the State University of New York (SUNY), operating as Upstate Medical Center, for the period of December 1, 2024 to April 30, 2026. The grant will fund research to elucidate the molecular mechanisms underlying the interaction between the intrinsically disordered protein ABI1 and the androgen receptor (AR) in prostate cancer. Specifically,...